ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)

OBJECTIVES: We evaluated the efficacy and safety of dapagliflozin, a SGLT2i along with ARNI in refractory HFrEF irrespective of their diabetic status. METHODS: We performed a retrospective analysis of 104 symptomatic patients of HFrEF despite of optimal medical management with ARNI between January–J...

Descripción completa

Detalles Bibliográficos
Autores principales: Jariwala, Pankaj, Jadhav, Kartik, Punjani, Arshad, Boorugu, Harikishan, Mari, Ajay Reddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514411/
https://www.ncbi.nlm.nih.gov/pubmed/34627577
http://dx.doi.org/10.1016/j.ihj.2021.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514411/
https://www.ncbi.nlm.nih.gov/pubmed/34627577
http://dx.doi.org/10.1016/j.ihj.2021.07.005

Ejemplares similares